How to cite this WIREs title:
WIREs RNA

Delivery of RNAi mediators

Focus Article

Lance P. Ford, Masoud M. Toloue

Published Online: Jun 03 2010

DOI: 10.1002/wrna.12

How to cite this article
Download citation
Contact the editor about this article
Authors: submit updates and notes
Comment on this article
Share

Full article on Wiley Online Library: HTML PDF

Can't access this content? Tell your librarian.

Delivering polynucleotides into animals has been a major challenge facing their success as therapeutic agents. Given the matured understanding of antibody‐mediated delivery techniques, it is possible to rationally design delivery vehicles that circulate in the blood stream and are specifically delivered into target organs. If the targeting moiety is designed to contain the cargo of an RNAi mediator without impacting its paratope, directed delivery can be achieved. In this article, we review the state of art in delivery technology for RNA mediators and address how this technique could soon be used to enhance the efficacy of the numerous small RNA therapeutic programs currently under evaluation. Copyright © 2010 John Wiley & Sons, Ltd.

This WIREs title offers downloadable PowerPoint presentations of figures for non-profit, educational use, provided the content is not modified and full credit is given to the author and publication.

Download a PowerPoint presentation of all images

Figure 1.

The analysis of knockdown of GAPDH in SKBR3 or MCF7 xenograft tumor cells using receptor‐mediated siRNA delivery. We added 50‐ng GAPDH siRNA or a scrambled negative‐control siRNA with 100 ng of HER2 antibody conjugate. This complex was incubated for 30 min at room temperature and then injected directly into xenograft tumors made using either SKBR3 or MCF7 cell lines. Seventy‐two hours postinjection, the animals were sacrificed, and tumors were removed and analyzed using an in‐house GAPDH ELISA assay. The relative gene reduction compared with scrambled negative controls was determined. The circular panel illustrates a xenograft tumor that was generated in NOD/SCID mice before delivery of the T3 conjugate.

[ Normal View 34K | Magnified View 55K ]

References

1 Fire, A, Xu, S, Montgomery, MK, Kostas, SA, Driver, SE, Mello, CC. Potent and specific genetic interference by double‐stranded RNA in Caenorhabditis elegans. Nature 1998, 391: 806–811.
2 Han, SE, Kang, H, Shim, GY, Kim, SJ, Choi, HG, Kim, J, Hahn, SK, Oh, YK. Cationic derivatives of biocompatible hyaluronic acids for delivery of siRNA and antisense oligonucleotides. J Drug Target 2009, 17: 123–132.
3 Howard, KA. Delivery of RNA interference therapeutics using polycation‐based nanoparticles. Adv Drug Deliv Rev 2009, 61: 710–720.
4 Tseng, YC, Mozumdar, S, Huang, L. Lipid‐based systemic delivery of siRNA. Adv Drug Deliv Rev 2009, 61: 721–731.
5 Zhang, C, Newsome, JT, Mewani, R, Pei, J, Gokhale, PC, Kasid, UN. Systemic delivery and pre‐clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs. Methods Mol Biol 2009, 480: 65–83.
6 Gao, S, Dagnaes‐Hansen, F, Nielsen, EJ, Wengel, J, Besenbacher, F, Howard, KA, Kjems, J. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther 2009, 17: 1225–1233.
7 Kariko, K, Bhuyan, P, Capodici, J, Ni, H, Lubinski, J, Friedman, H, Weissman, D. Exogenous siRNA mediates sequence‐independent gene suppression by signaling through toll‐like receptor 3. Cells Tissues Organs 2004, 177: 132–138.
8 Cho, WG, Albuquerque, RJ, Kleinman, ME, Tarallo, V, Greco, A, Nozaki, M, Green, MG, Baffi, JZ, Ambati, BK, De Falco, M, et al. Small interfering RNA‐induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci U S A 2009, 106: 7137–7142.
9 Morrissey, DV, Blanchard, K, Shaw, L, Jensen, K, Lockridge, JA, Dickinson, B, McSwiggen, JA, Vargeese, C, Bowman, K, Shaffer, CS, et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 2005, 41: 1349–1356.
10 Morrissey, DV, Lockridge, JA, Shaw, L, Blanchard, K, Jensen, K, Breen, W, Hartsough, K, Machemer, L, Radka, S, Jadhav, V, et al. Potent and persistent in vivo anti‐HBV activity of chemically modified siRNAs. Nat Biotechnol 2005, 23: 1002–1007.
11 Zimmermann, TS, Lee, AC, Akinc, A, Bramlage, B, Bumcrot, D, Fedoruk, MN, Harborth, J, Heyes, JA, Jeffs, LB, John, M, et al. RNAi‐mediated gene silencing in non‐human primates. Nature 2006, 441: 111–114.
12 Alshamsan, A, Haddadi, A, Incani, V, Samuel, J, Lavasanifar, A, Uludag, H. Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine. Mol Pharm 2009, 6: 121–133.
13 Andersen, MO, Howard, KA, Kjems, J. RNAi using a chitosan/siRNA nanoparticle system: in vitro and in vivo applications. Methods Mol Biol 2009, 555: 77–86.
14 Subramanian, N, Mani, P, Roy, S, Gnanasundram, SV, Sarkar, DP, Das, S. Targeted delivery of hepatitis C virus‐specific short hairpin RNA in mouse liver using Sendai virosomes. J Gen Virol 2009, 90: 1812–1819.
15 Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M, Elbashir, S, Geick, A, Hadwiger, P, Harborth, J, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432: 173–178.
16 Manoharan, M. RNA interference and chemically modified siRNAs. Nucleic Acids Res Suppl 2003, 3: 115–116.
17 Manoharan, M. RNA interference and chemically modified small interfering RNAs. Curr Opin Chem Biol 2004, 8: 570–579.
18 Akinc, A, Goldberg, M, Qin, J, Dorkin, JR, Gamba‐Vitalo, C, Maier, M, Jayaprakash, KN, Jayaraman, M, Rajeev, KG, Manoharan, M, et al. Development of lipidoid‐siRNA formulations for systemic delivery to the liver. Mol Ther 2009, 17: 872–879.
19 Wolfrum, C, Shi, S, Jayaprakash, KN, Jayaraman, M, Wang, G, Pandey, RK, Rajeev, KG, Nakayama, T, Charrise, K, Ndungo, EM, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007, 25: 1149–1157.
20 Bitko, V, Musiyenko, A, Shulyayeva, O, Barik, S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005, 11: 50–55.
21 Li, BJ, Tang, Q, Cheng, D, Qin, C, Xie, FY, Wei, Q, Xu, J, Liu, Y, Zheng, BJ, Woodle, MC, et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 2005, 11: 944–951.
22 Grillot‐Courvalin, C, Goussard, S, Huetz, F, Ojcius, DM, Courvalin, P. Functional gene transfer from intracellular bacteria to mammalian cells. Nat Biotechnol 1998, 16: 862–866.
23 Palliser, D, Chowdhury, D, Wang, QY, Lee, SJ, Bronson, RT, Knipe, DM, Lieberman, J. An siRNA‐based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 2006, 439: 89–94.
24 Santel, A, Aleku, M, Keil, O, Endruschat, J, Esche, V, Fisch, G, Dames, S, Loffler, K, Fechtner, M, Arnold, W, et al. A novel siRNA‐lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 2006, 13: 1222–1234.
25 Xiang, S, Fruehauf, J, Li, CJ. Short hairpin RNA‐expressing bacteria elicit RNA interference in mammals. Nat Biotechnol 2006, 24: 697–702.
26 Yang, R, Yang, X, Zhang, Z, Zhang, Y, Wang, S, Cai, Z, Jia, Y, Ma, Y, Zheng, C, Lu, Y, et al. Single‐walled carbon nanotubes‐mediated in vivo and in vitro delivery of siRNA into antigen‐presenting cells. Gene Ther 2006, 13: 1714–1723.
27 Agrawal, A, Min, DH, Singh, N, Zhu, H, Birjiniuk, A, von Maltzahn, G, Harris, TJ, Xing, D, Woolfenden, SD, Sharp, PA, et al. Functional delivery of siRNA in mice using dendriworms. ACS Nano 2009, 3: 2495–2504.
28 Mathupala, SP. Delivery of small‐interfering RNA (siRNA) to the brain. Expert Opin Ther Pat 2009, 19: 137–140.
29 Pardridge, WM. Intravenous, non‐viral RNAi gene therapy of brain cancer. Expert Opin Biol Ther 2004, 4: 1103–1113.
30 Reimer, DL, Zhang, Y, Kong, S, Wheeler, JJ, Graham, RW, Bally, MB. Formation of novel hydrophobic complexes between cationic lipids and plasmid DNA. Biochemistry 1995, 34: 12877–12883.
31 Huang, L, Li, S. Liposomal gene delivery: a complex package. Nat Biotechnol 1997, 15: 620–621.
32 Mahato, RI, Rolland, A, Tomlinson, E. Cationic lipid‐based gene delivery systems: pharmaceutical perspectives. Pharm Res 1997, 14: 853–859.
33 Matsui, H, Johnson, LG, Randell, SH, Boucher, RC. Loss of binding and entry of liposome‐DNA complexes decreases transfection efficiency in differentiated airway epithelial cells. J Biol Chem 1997, 272: 1117–1126.
34 Huwyler, J, Wu, D, Pardridge, WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A 1996, 93: 14164–14169.
35 Xia, CF, Zhang, Y, Boado, RJ, Pardridge, WM. Intravenous siRNA of brain cancer with receptor targeting and avidin‐biotin technology. Pharm Res 2007, 24: 2309–2316.
36 Whelan, J. Beyond PEGylation. Drug Discov Today 2005, 10: 301.
37 Whelan, J. First clinical data on RNAi. Drug Discov Today 2005, 10: 1014–1015.
38 Tolentino, MJ, Brucker, AJ, Fosnot, J, Ying, GS, Wu, IH, Malik, G, Wan, S, Reich, SJ. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser‐induced model of choroidal neovascularization. Retina 2004, 24: 660.
39 Reich, SJ, Fosnot, J, Kuroki, A, Tang, W, Yang, X, Maguire, AM, Bennett, J, Tolentino, MJ. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003, 9: 210–216.
40 Nakamura, H, Siddiqui, SS, Shen, X, Malik, AB, Pulido, JS, Kumar, NM, Yue, BY. RNA interference targeting transforming growth factor‐beta type II receptor suppresses ocular inflammation and fibrosis. Mol Vis 2004, 10: 703–711.
41 Singerman, L. Combination therapy using the small interfering RNA bevasiranib. Retina 2009, 29(Suppl 6): S49–S50.
42 Kleinman, ME, Yamada, K, Takeda, A, Chandrasekaran, V, Nozaki, M, Baffi, JZ, Albuquerque, RJ, Yamasaki, S, Itaya, M, Pan, Y, et al. Sequence‐ and target‐independent angiogenesis suppression by siRNA via TLR3. Nature 2008, 452: 591–597.
43 Barik, S. Development of gene‐specific double‐stranded RNA drugs. Ann Med 2004, 36: 540–551.
44 Barik, S. Treating respiratory viral diseases with chemically modified, second generation intranasal siRNAs. Methods Mol Biol 2009, 487: 331–341.
45 Duxbury, MS, Ito, H, Zinner, MJ, Ashley, SW, Whang, EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004, 23: 1539–1548.
46 Xu, L, Huang, CC, Huang, W, Tang, WH, Rait, A, Yin, YZ, Cruz, I, Xiang, LM, Pirollo, KF, Chang, EH. Systemic tumor‐targeted gene delivery by anti‐transferrin receptor scFv‐immunoliposomes. Mol Cancer Ther 2002, 1: 337–346.
47 Kovar, H, Ban, J, Pospisilova, S. Potentials for RNAi in sarcoma research and therapy: Ewing`s sarcoma as a model. Semin Cancer Biol 2003, 13: 275–281.
48 Davis, ME. The first targeted delivery of siRNA in humans via a self‐assembling, cyclodextrin polymer‐based nanoparticle: from concept to clinic. Mol Pharm 2009, 6: 659–668.
49 Krutzfeldt, J, Rajewsky, N, Braich, R, Rajeev, KG, Tuschl, T, Manoharan, M, Stoffel, M. Silencing of microRNAs in vivo with ‘antagomirs’ Nature 2005, 483: 685–689..
50 Pappas, TC, Bader, AG, Andruss, BF, Brown, D, Ford, LP. Applying small RNA molecules to the directed treatment of human diseases: realizing the potential. Expert Opin Ther Targets 2008, 12: 115–127.
51 Blackburn, WH, Dickerson, EB, Smith, MH, McDonald, JF, Lyon, LA. Peptide‐functionalized nanogels for targeted siRNA delivery. Bioconjug Chem 2009, 20: 960–968.
52 Jeong, JH, Mok, H, Oh, YK, Park, TG. siRNA conjugate delivery systems. Bioconjug Chem 2009, 20: 5–14.
53 Wullner, U, Neef, I, Tur, MK, Barth, S. Targeted delivery of short interfering RNAs–strategies for in vivo delivery. Recent Pat Anticancer Drug Discov 2009, 4: 1–8.
54 Yu, B, Zhao, X, Lee, LJ, Lee, RJ. Targeted delivery systems for oligonucleotide therapeutics. AAPS J 2009, 11: 195–203.
55 Zheng, X, Vladau, C, Zhang, X, Suzuki, M, Ichim, TE, Zhang, ZX, Li, M, Carrier, E, Garcia, B, Jevnikar, AM, et al. A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood 2009, 113: 2646–2654.
56 Lorenz, C, Hadwiger, P, John, M, Vornlocher, HP, Unverzagt, C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 2004, 14: 4975–4977.
57 Wang, XL, Xu, R, Lu, ZR. A peptide‐targeted delivery system with pH‐sensitive amphiphilic cell membrane disruption for efficient receptor‐mediated siRNA delivery. J Control Release 2009, 134: 207–213.
58 Pirollo, KF, Chang, EH. Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res 2008, 68: 1247–1250.
59 Pirollo, KF, Rait, A, Zhou, Q, Hwang, SH, Dagata, JA, Zon, G, Hogrefe, RI, Palchik, G, Chang, EH. Materializing the potential of small interfering RNA via a tumor‐targeting nanodelivery system. Cancer Res 2007, 67: 2938–2943.
60 Pirollo, KF, Zon, G, Rait, A, Zhou, Q, Yu, W, Hogrefe, R, Chang, EH. Tumor‐targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther 2006, 17: 117–124.
61 Song, E, Zhu, P, Lee, SK, Chowdhury, D, Kussman, S, Dykxhoorn, DM, Feng, Y, Palliser, D, Weiner, DB, Shankar, P, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell‐surface receptors. Nat Biotechnol 2005, 23: 709–717.
62 Kumar, P, Ban, HS, Kim, SS, Wu, H, Pearson, T, Greiner, DL, Laouar, A, Yao, J, Haridas, V, Habiro, K, et al. T cell‐specific siRNA delivery suppresses HIV‐1 infection in humanized mice. Cell 2008, 134: 577–586.
63 Tuschl, T, Zamore, PD, Lehmann, R, Bartel, DP, Sharp, PA. Targeted mRNA degradation by double‐stranded RNA in vitro. Genes Dev 1999, 13: 3191–3197.
64 Parrish, S, Fleenor, J, Xu, S, Mello, C, Fire, A. Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. Mol Cell 2000, 6: 1077–1087.
65 Zamore, PD, Tuschl, T, Sharp, PA, Bartel, DP. RNAi: double‐stranded RNA directs the ATP‐dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000, 101: 25–33.
66 Elbashir, SM, Lendeckel, W, Tuschl, T. RNA interference is mediated by 21‐ and 22‐nucleotide RNAs. Genes Dev 2001, 15: 188–200.
67 Peer, D, Zhu, P, Carman, CV, Lieberman, J, Shimaoka, M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function‐associated antigen‐1. Proc Natl Acad Sci U S A 2007, 104: 4095–4100.
68 Liu, Z, Winters, M, Holodniy, M, Dai, H. siRNA delivery into human T cells and primary cells with carbon‐nanotube transporters. Angew Chem Int Ed Engl 2007, 46: 2023–2027.
69 Duffy, MJ. Predictive markers in breast and other cancers: a review. Clin Chem 2005, 51: 494–503.
70 Ono, M, Kuwano, M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR‐targeting drugs. Clin Cancer Res 2006, 12: 7242–7251.
71 Meden, H, Kuhn, W. Overexpression of the oncogene c‐erbB‐2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur J Obstet Gynecol Reprod Biol 1997, 71: 173–179.
72 Dykxhoorn, DM, Lieberman, J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med 2005, 56: 401–423.
73 Schiffelers, RM, Ansari, A, Xu, J, Zhou, Q, Tang, Q, Storm, G, Molema, G, Lu, PY, Scaria, PV, Woodle, MC. Cancer siRNA therapy by tumor selective delivery with ligand‐targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004, 32: e149.
74 Kim, SH, Mok, H, Jeong, JH, Kim, SW, Park, TG. Comparative evaluation of target‐specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI‐PEG‐FOL conjugate. Bioconjug Chem 2006, 17: 241–244.
75 Peer, D, Park, EJ, Morishita, Y, Carman, CV, Shimaoka, M. Systemic leukocyte‐directed siRNA delivery revealing cyclin D1 as an anti‐inflammatory target. Science 2008, 319: 627–630.
76 Daniels, TR, Delgado, T, Helguera, G, Penichet, ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 2006, 121: 159–176.
77 Daniels, TR, Delgado, T, Rodriguez, JA, Helguera, G, Penichet, ML. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006, 121: 144–158.
78 Chen, QR, Zhang, L, Luther, PW, Mixson, AJ. Optimal transfection with the HK polymer depends on its degree of branching and the pH of endocytic vesicles. Nucleic Acids Res 2002, 30: 1338–1345.
79 Aoki, Y, Hosaka, S, Kawa, S, Kiyosawa, K. Potential tumor‐targeting peptide vector of histidylated oligolysine conjugated to a tumor‐homing RGD motif. Cancer Gene Ther 2001, 8: 783–787.

blog comments powered by Disqus

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

In the Spotlight

Yingqun Huang

and her research team focus on the dissection of the molecular mechanisms and pathways involved in Lin28-mediated regulation. First, they will analyze Lin28 expression in mouse and human ES cells to determine whether its expression is regulated during the cell cy-cle. Then, they will characterize the interactions between Lin28 and its associated mRNAs to gain molecular insights into their assembly, function and regulation in the cellular milieu. Finally, they will strive to identify Lin28-interacting protein partners and new target mRNAs to establish a comprehensive and global understanding of Lin28 function.

Learn More

Article Title	Delivery of RNAi mediators
* Name
* E-mail
* Note

Delivery of RNAi mediators

Related Articles

Browse by Topic

Access to this WIREs title is by subscription only.

The latest WIREs articles in your inbox

In the Spotlight

Twitter: WIREsrna Follow us on Twitter